Cardiovascular risk and glycemic control.
Cheng
Alice Y Y
AY
Division of Endocrinology and Metabolism, St. Michael's Hospital, University of Toronto, Toronto, Ont. chenga@smh.toronto.on.ca
Leiter
Lawrence A
LA
D015415:Biomarkers / Q000378:metabolism; D001786:Blood Glucose; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control*; D015984:Causality; D002986:Clinical Trials as Topic; D015897:Comorbidity; D048909:Diabetes Complications / Q000453:epidemiology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D006943:Hyperglycemia / Q000453:epidemiology / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D007333:Insulin Resistance; D011486:Protein C / Q000378:metabolism; D012107:Research Design; D018570:Risk Assessment; D016896:Treatment Outcome
D015415:Biomarkers; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D011486:Protein C